Medigen Biotechnology
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has complete… Read more
Medigen Biotechnology (3176) - Total Assets
Latest total assets as of September 2025: NT$6.34 Billion TWD
Based on the latest financial reports, Medigen Biotechnology (3176) holds total assets worth NT$6.34 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medigen Biotechnology - Total Assets Trend (2003–2024)
This chart illustrates how Medigen Biotechnology’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Medigen Biotechnology - Asset Composition Analysis
Current Asset Composition (December 2024)
Medigen Biotechnology's total assets of NT$6.34 Billion consist of 54.6% current assets and 45.4% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 20.7% |
| Accounts Receivable | NT$201.24 Million | 3.0% |
| Inventory | NT$645.06 Million | 9.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how Medigen Biotechnology's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medigen Biotechnology's current assets represent 54.6% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2024, up from 5.3% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 47.0% in 2003.
- Asset Diversification: The largest asset category is inventory at 9.6% of total assets.
Medigen Biotechnology Competitors by Total Assets
Key competitors of Medigen Biotechnology based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Medigen Biotechnology - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Medigen Biotechnology generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Medigen Biotechnology is currently not profitable relative to its asset base.
Medigen Biotechnology - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.12 | 4.07 | 3.24 |
| Quick Ratio | 4.16 | 3.38 | 2.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$2.86 Billion | NT$ 2.77 Billion | NT$ 2.09 Billion |
Medigen Biotechnology - Advanced Valuation Insights
This section examines the relationship between Medigen Biotechnology's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.69 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -21.3% |
| Total Assets | NT$6.71 Billion |
| Market Capitalization | $100.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medigen Biotechnology's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Medigen Biotechnology's assets decreased by 21.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Medigen Biotechnology (2003–2024)
The table below shows the annual total assets of Medigen Biotechnology from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$6.71 Billion | -21.31% |
| 2023-12-31 | NT$8.53 Billion | -14.58% |
| 2022-12-31 | NT$9.98 Billion | +21.74% |
| 2021-12-31 | NT$8.20 Billion | +33.27% |
| 2020-12-31 | NT$6.15 Billion | +27.41% |
| 2019-12-31 | NT$4.83 Billion | +5.01% |
| 2018-12-31 | NT$4.60 Billion | -5.60% |
| 2017-12-31 | NT$4.87 Billion | +1.01% |
| 2016-12-31 | NT$4.82 Billion | +7.30% |
| 2015-12-31 | NT$4.49 Billion | +0.69% |
| 2014-12-31 | NT$4.46 Billion | +35.49% |
| 2013-12-31 | NT$3.29 Billion | +47.04% |
| 2012-12-31 | NT$2.24 Billion | +84.46% |
| 2011-12-31 | NT$1.21 Billion | +39.64% |
| 2010-12-31 | NT$869.78 Million | +28.05% |
| 2009-12-31 | NT$679.27 Million | -0.25% |
| 2008-12-31 | NT$680.98 Million | +14.83% |
| 2007-12-31 | NT$593.03 Million | -20.17% |
| 2006-12-31 | NT$742.89 Million | +5.80% |
| 2005-12-31 | NT$702.17 Million | -8.52% |
| 2004-12-31 | NT$767.53 Million | -20.61% |
| 2003-12-31 | NT$966.81 Million | -- |